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2352-3964/© 2017 The Author(s). Published by Elsevier BWith about 3–5 million severe cases and 250.000–500.000 deaths
yearly, seasonal inﬂuenza infections form a constant and serious threat
to the human population (Inﬂuenza (Seasonal) Fact sheet, n.d.). In addi-
tion, new inﬂuenza virus strains, often originating in birds or pigs, may
cross the species barrier to humans and cause pandemics with poten-
tially very high attack rates and sometimes high mortality (Trombetta
et al., 2015). While vaccination can protect from seasonal inﬂuenza
strains it will be of limited use in the ﬁrst months of a pandemic since
vaccine production and distribution will lag behind as experienced dur-
ing the Swine Flu in 2009. Antivirals can provide an outcome and in fact
have been stockpiled by several countries as a ﬁrst line of defence in
case of a pandemic. Yet, inﬂuenza virus appears to rapidly acquire resis-
tance against antivirals. Thus, new intervention options are urgently
needed.
Intravenous immunoglobulin (IVIg) preparations consist of pooled
serum IgG fractions from several thousand individuals. Originally
employed as replacement therapy for immunodeﬁcient individuals,
IVIg is currently recognized as an immunomodulating intervention suit-
able for treatment of a variety of autoimmune, infectious and idiopathic
diseases (Scheinfeld, 2016). IVIg has been used sporadically for treat-
ment of inﬂuenza patients, mainly with the idea that the preparation
will contain inﬂuenza-speciﬁc antibodies which can interfere with the
infecting virus. Indeed, inﬂuenza-speciﬁc antibodies with broad speci-
ﬁcity have been found in IVIg preparations and proved to mediate anti-
body-dependent cellular cytotoxicity (ADCC) in vitro (Jegaskanda et al.,
2014).
In this issue of EBioMedicine, Rockman and co-workers report on a
study into the in vivo effects of IVIg therapy using ferrets as a well-
established animal model for inﬂuenza (Rockman et al., 2017–in this
issue). The study demonstrates that IVIg preparations from before
2009 have the capacity to ameliorate disease symptoms in ferrets in-
fected with 2009 H1N1pdm virus, and protect from death caused by in-
fection with lethal H5N1 virus. Thus, IVIg preparations provided
protection although they did not contain antibodies elicited by the chal-
lenge viruses. This is an important observation which implies that IVIg
can be used as treatment option for newly emerging virus strains.
In a series of well-designed experiments the authors tried to unravel
the mechanism of action of IVIg in vivo. They observed that theom.2017.04.010.
oningen, Hanzeplein 1, P.O. Box
.V. This is an open access article undprotective effect was independent of virus-neutralizing, hemagglutina-
tion-inhibiting and neuraminidase-speciﬁc antibodies. Even when pre-
absorbed with inﬂuenza virus, IVIg still had protective activity. F(ab′)2
fragments were equally potent as entire antibodies while Fc fragments
were inactive. This indicates that the antigen binding region of the anti-
bodies is important for the protective effect. Moreover, protection by
F(ab)2 fragments alone rules out the possibility, at least in this model,
that mechanisms relying on complement activation, ADCC or anti-
body-dependent phagocytosis (ADP) are crucial for the observed pro-
tection. Also, induction of anti-inﬂammatory IL10 could be ruled out
as an essential mechanism. Thus, despite all the attempts made the au-
thors could not reveal how IVIg affords protection against inﬂuenza in-
fection. They speculate that low levels of cross-reactive antibodies
present in IVIg preparation might be responsible for the observed
effects.
Withmanyof the ‘usual suspects’ eliminatedwhat else could explain
the effect of IVIg on inﬂuenza infection and course of disease? Studies
into possible targets of IVIg antibodies have revealed among others
anaphylatoxins and cytokines which would be in line with an anti-in-
ﬂammatory effect of IVIg [reviewed in (Schwab and Nimmerjahn,
2013)]. Indeed, preclinical and clinical studies emphasize that treat-
ment of inﬂuenza infections with anti-inﬂammatory drugs canmitigate
disease symptomswithout having an effect on lung virus titers (Howard
et al., 2011). Furthermore, IVIg preparations have been shown to con-
tain large amounts of carbohydrate-binding antibodies (van Gunten et
al., 2009). As inﬂuenza virus uses sialic acid residues on membrane gly-
coproteins of epithelial cells as a receptor, carbohydrate-binding anti-
bodies may shield receptor binding sites of the virus thus preventing
cellular infection.
Sialic acid residues might also play a role in another way. IgG prepa-
rations contain large amounts of sialylated antibodies and recent studies
have demonstrated that these are crucial for the anti-inﬂammatory ef-
fects of IVIg [reviewed in (Schwab and Nimmerjahn, 2014)]. Both the
F(ab)2 part as well as the Fc part of the antibodies can contain sialic-
acid residues. Yet, while the immunosuppressive role of sialylation of
the Fc part is undisputed, data on the role of sialylation of the F(ab)2
part for anti-inﬂammatory effects is less clear. Sialylated F(ab′)2 parts
may, however, have yet another function. A recent study indicates
that they can serve as decoy receptors for inﬂuenza virus thus
preventing binding of the virus to its target cells (Huang et al., 2013).
Even though the precise mechanism of action remains elusive evi-
dence has accumulated that IVIg might be an effective therapy for se-
vere inﬂuenza. A big asset is that IVIg preparations are readily
available and IVIg therapy is already well established in the clinic. Oner the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
11A. Huckriede / EBioMedicine 19 (2017) 10–11the downside, large amounts of antibodies are required for the antiviral
effect,making use of IVIg aswidespread therapy difﬁcult and expensive.
Moreover, the therapy needs to start as early as possible after infection
for maximal effectiveness. Given the fact that ﬂu-like symptoms are
very common for a range of infections, early detection of inﬂuenza-in-
fected individuals might be difﬁcult. However, with a further improved
understanding of how IVIg exerts its anti-inﬂuenza effects it might be
possible to developmore effective preparations. In addition, rapid inﬂu-
enza diagnostic tests can help in the early detection of infected individ-
uals to expedite the start of treatment for maximal therapeutic effect.
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